1
|
Tsang DSC, Tsui G, Santiago AT, Keller H, Purdie TG, McIntosh C, La Macchia N, Parent A, Dama H, Ahmed S, Craig T, Laperriere NJ, Millar BA, Hodgson D. A Prospective Study of Machine Learning-Assisted Radiotherapy Planning for Patients Receiving 54 Gy to the Brain. Int J Radiat Oncol Biol Phys 2023; 117:S19. [PMID: 37784448 DOI: 10.1016/j.ijrobp.2023.06.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Radiotherapy (RT) planning is presently a semi-manual, iterative, labor-intensive process which may result in unnecessary variation in plan quality. To improve treatment plan quality and decrease RT planning time, we conducted a prospective, blinded study to compare machine learning-assisted planning with conventional manual planning for patients receiving 54 Gy in 30 fractions for a primary brain tumor. MATERIALS/METHODS From January 31, 2022 to January 10, 2023, 40 patients receiving 54 Gy for primary CNS tumors were prospectively enrolled (median age 50 years, range 4-78 years). Patients underwent standard CT/MR simulation and target/OAR delineation by the treating radiation oncologist. Each patient had one ML plan and 1-2 manual RT plans created by different planners. The reviewing oncologist was blinded to planning method by removing optimization and IMRT/VMAT beam arrangement details from all plans, which were then rated based on clinical acceptability, target coverage, OAR sparing, conformity, and dose-fall off. One preferred plan was chosen and used for clinical treatment. RESULTS A total of 115 plans for 40 patients were evaluated: 40 ML plans (35% of all plans), and 75 manual plans (65% of all plans; 5 and 35 patients had 1 and 2 manual plans created, respectively). ML plans required a mean planning time of 65 min as compared to 107 min for manual plans, with a mean time savings of 41 min per patient (paired t-test p = 0.002). 97% of ML plans (95% confidence interval [CI] 85-100) and 96% of manual plans (95% CI 87-99) were designated clinically acceptable by the treating radiation oncologist. While ML-assisted plans represented 35% of plans evaluated, they were chosen as preferred for clinical treatment in 43% of cases (17/40, 95% CI 29-58, p = 0.32). Median doses to the brain (10.8 Gy vs. 11.3 Gy, Wilcoxon rank-sum p = 0.012) and brain minus PTV (9.2 Gy vs 10.0 Gy, Wilcoxon rank-sum p = 0.009) were lower with ML planning versus manual planning, respectively. Doses to other structures, including hippocampi, cochlea, pituitary and hypothalamus were not statistically different. CONCLUSION In this prospective study with blinded oncologist evaluation, ML-assisted RT planning for primary CNS tumors was faster than manual planning, and produced a very high rate of acceptable plans with similar or superior OAR sparing. Future work will be undertaken to iteratively refine the ML model using the preferred cases from this study.
Collapse
Affiliation(s)
- D S C Tsang
- Radiation Medicine Program, Princess Margaret Cancer Centre and Toronto Western Hospital, University Health Network, Toronto, ON, Canada
| | - G Tsui
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - A T Santiago
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - H Keller
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
| | | | - C McIntosh
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
| | - N La Macchia
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - A Parent
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - H Dama
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - S Ahmed
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - T Craig
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - N J Laperriere
- Radiation Medicine Program, Princess Margaret Cancer Centre and Toronto Western Hospital, University Health Network, Toronto, ON, Canada
| | - B A Millar
- Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
| | - D Hodgson
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
2
|
Rodin D, Banihashemi B, Wang L, Lau A, Harris S, Levin W, Dinniwell R, Millar BA, Chung C, Laperriere N, Bezjak A, Wong RKS. The Brain Metastases Symptom Checklist as a novel tool for symptom measurement in patients with brain metastases undergoing whole-brain radiotherapy. ACTA ACUST UNITED AC 2016; 23:e239-47. [PMID: 27330360 DOI: 10.3747/co.23.2936] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE We evaluated the feasibility, reliability, and validity of the Brain Metastases Symptom Checklist (bmsc), a novel self-report measure of common symptoms experienced by patients with brain metastases. METHODS Patients with first-presentation symptomatic brain metastases (n = 137) referred for whole-brain radiotherapy (wbrt) completed the bmsc at time points before and after treatment. Their caregivers (n = 48) provided proxy ratings twice on the day of consultation to assess reliability, and at week 4 after wbrt to assess responsiveness to change. Correlations with 4 other validated assessment tools were evaluated. RESULTS The symptoms reported on the bmsc were largely mild to moderate, with tiredness (71%) and difficulties with balance (61%) reported most commonly at baseline. Test-retest reliability for individual symptoms had a median intraclass correlation of 0.59 (range: 0.23-0.85). Caregiver proxy and patient responses had a median intraclass correlation of 0.52. Correlation of absolute scores on the bmsc and other symptom assessment tools was low, but consistency in the direction of symptom change was observed. At week 4, change in symptoms was variable, with improvements in weight gain and sleep of 42% and 41% respectively, and worsening of tiredness and drowsiness of 62% and 59% respectively. CONCLUSIONS The bmsc captures a wide range of symptoms experienced by patients with brain metastases, and it is sensitive to change. It demonstrated adequate test-retest reliability and face validity in terms of its responsiveness to change. Future research is needed to determine whether modifications to the bmsc itself or correlation with more symptom-specific measures will enhance validity.
Collapse
Affiliation(s)
- D Rodin
- Department of Radiation Oncology, University of Toronto, Toronto, ON
| | - B Banihashemi
- Department of Radiation Oncology, Lakeridge Health Corporation, Oshawa, ON
| | - L Wang
- Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON
| | - A Lau
- Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON
| | - S Harris
- Palliative Radiation Oncology Program, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - W Levin
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - R Dinniwell
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - B A Millar
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - C Chung
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - N Laperriere
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - A Bezjak
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| | - R K S Wong
- Department of Radiation Oncology, University of Toronto, Toronto, ON;; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
| |
Collapse
|
3
|
Tieu MT, Cigsar C, Ahmed S, Ng A, Diller L, Millar BA, Crystal P, Hodgson DC. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer 2014; 120:2507-13. [PMID: 24888639 PMCID: PMC4283737 DOI: 10.1002/cncr.28747] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Revised: 02/05/2014] [Accepted: 02/05/2014] [Indexed: 02/05/2023]
Abstract
BACKGROUND Female survivors of pediatric Hodgkin lymphoma (HL) who have received chest radiotherapy are at increased risk of breast cancer. Guidelines for early breast cancer screening among these survivors are based on little data regarding clinical outcomes. This study reports outcomes of breast cancer screening with MRI and mammography (MMG) after childhood HL. METHODS We evaluated the results of breast MRI and MMG screening among 96 female survivors of childhood HL treated with chest radiotherapy. Outcomes measured included imaging sensitivity and specificity, breast cancer characteristics, and incidence of additional imaging and breast biopsy. RESULTS Median age at first screening was 30 years, and the median number of MRI screening rounds was 3. Ten breast cancers were detected in 9 women at a median age of 39 years (range, 24-43 years). Half were invasive and half were preinvasive. The median size of invasive tumors was 8 mm (range, 3-15 mm), and none had lymph node involvement. Sensitivity and specificity of the screening modalities were as follows: for MRI alone, 80% and 93.5%, respectively; MMG alone, 70% and 95%, respectively; both modalities combined, 100% and 88.6%, respectively. All invasive tumors were detected by MRI. Additional investigations were required in 52 patients, (54%), and 26 patients (27%) required breast biopsy, with 10 patients requiring more than 1 biopsy. CONCLUSIONS Screening including breast MRI with MMG has high sensitivity and specificity in pediatric HL survivors, with breast cancers detected at an early stage, although it is associated with a substantial rate of additional investigations. Cancer 2014;120:2507–2513. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. Screening female survivors of pediatric Hodgkin Lymphoma for breast cancer with MRI and mammography detected tumors at an earlier stage than prior studies of mammography alone, although a substantial proportion of women required additional tests for benign imaging findings. The 5-year cumulative incidence of invasive or preinvasive tumors after initiating screening was 10.8%.
Collapse
Affiliation(s)
- Minh Thi Tieu
- Radiation Medicine Program, Princess Margaret Hospital, and the Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Foote M, Millar BA, Sahgal A, Ménard C, Payne D, Mason W, Laperriere N. Clinical outcomes of adult patients with primary intracranial germinomas treated with low-dose craniospinal radiotherapy and local boost. J Neurooncol 2010; 100:459-63. [PMID: 20455001 DOI: 10.1007/s11060-010-0206-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2009] [Accepted: 04/14/2010] [Indexed: 12/17/2022]
Abstract
The authors document the long term follow up of adult patients with histologically proven primary intracranial germinoma treated with radiotherapy alone using a craniospinal with local boost technique. A retrospective review was conducted on adults diagnosed with intracranial germinoma who received radiotherapy at the Princess Margaret Hospital, Toronto from 1990 to 2007. The study group consisted of 10 males with a median age of 24.1 years. All patients received radiotherapy alone using craniospinal radiotherapy and local boost. There were 10 patients (all male) with a median follow up of 10.9 years (range 2.2-18.9 years). At date of last follow up all patients were still alive, none with relapsed disease. Seven of ten patients (70%) had panhypopituitarianism prior to commencing radiotherapy and hormonal function was not affected in those with an intact pituitary axis. There was no reported cognitive decline in the treated cohort. For adult intracranial germinomas, with long term follow up, low-dose craniospinal radiotherapy with in field boost is highly effective with minimal morbidity.
Collapse
Affiliation(s)
- M Foote
- Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
| | | | | | | | | | | | | |
Collapse
|
5
|
Sadikov E, Bezjak A, Yi QL, Wells W, Dawson L, Millar BA, Laperriere N. Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol) 2007; 19:532-8. [PMID: 17662582 DOI: 10.1016/j.clon.2007.06.001] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2006] [Revised: 05/09/2007] [Accepted: 06/05/2007] [Indexed: 11/23/2022]
Abstract
AIMS There is controversy in published studies regarding the role of repeat whole brain radiation (WBRT) for previously irradiated brain metastases. The aim of our retrospective study was to document the practice at Princess Margaret Hospital with respect to the re-irradiation of patients with progressive or recurrent brain metastatic disease after initial WBRT. MATERIALS AND METHODS A comprehensive computerised database was used to identify patients treated for brain metastases with more than one course of WBRT between 1997 and 2003. Seventy-two patients were treated with WBRT for brain metastases and retreated with WBRT at a later date. The records of these patients were reviewed. RESULTS The median age was 56.5 years. The most common primary sites were lung (51 patients) and breast (17 patients). The most frequent dose used for the initial radiotherapy was 20 Gy/5 fractions (62 patients). The most common doses of re-irradiation were 25 Gy/10 fractions (22 patients), 20 Gy/10 fractions (12 patients), 15 Gy/5 fractions (11 patients) and 20 Gy/8 fractions (10 patients). Thirty-one per cent of patients experienced a partial clinical response after re-irradiation, as judged by follow-up clinical notes; 27% remained stable; 32% deteriorated after re-irradiation. Patients who had Eastern Cooperative Oncology Group performance status 0-1 at the time of retreatment lived longer. In responders, the mean duration of response was 5.1 months. The median survival after re-irradiation was 4.1 months. One patient was reported as having memory impairment and pituitary insufficiency after 5 months of progression-free survival. CONCLUSION Repeat radiotherapy may be a useful treatment in carefully selected patients. With increased survival and better systemic options for patients with metastatic disease, more patients may be candidates for consideration of repeat WBRT for recurrent brain metastases, but prospective studies are needed to more clearly document their outcomes.
Collapse
Affiliation(s)
- E Sadikov
- Radiation Oncology Department, Allan Blair Cancer Centre, University of Saskatchewan, Regina, Canada
| | | | | | | | | | | | | |
Collapse
|
6
|
Sahgal A, Millar BA, Michaels H, Jaywant S, Chan HSL, Heon E, Gallie B, Laperriere N. Focal Stereotactic External Beam Radiotherapy as a Vision-sparing Method for the Treatment of Peripapillary and Perimacular Retinoblastoma: Preliminary Results. Clin Oncol (R Coll Radiol) 2006; 18:628-34. [PMID: 17051954 DOI: 10.1016/j.clon.2006.06.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
AIMS Chemotherapy with aggressive focal ablative therapy is now the mainstay of retinoblastoma therapy. Our experience presents an evolution from conventional radiotherapy by treating posterior pole tumours with focal stereotactic fractionated radiotherapy (SRT). MATERIALS AND METHODS A retrospective chart review was conducted of five patients (six eyes) treated with SRT at the Hospital for Sick Children and Princess Margaret Hospital, Toronto, Canada, between 1999 and 2004. The prescribed dose was 40 Gy delivered in 20 fractions once daily using 6 MV photons. RESULTS Five patients (six eyes) were treated. The median age at the time of SRT was 18 months. The median follow-up was 46.5 months as of September 2004. Four patients were treated for a posterior pole focal tumour by focal SRT, and one patient was treated for vitreous seeding with whole-eye SRT. In patients treated with focal SRT, the median doses to the tumour, optic chiasm and brainstem were 41.92, 0.25 and 0.07 Gy, respectively, and to the ipsilateral optic nerve, globe and lens were 9.98, 19.11 and 3.74 Gy, respectively. The median doses to the ipsilateral and contralateral orbital bone were 6.73 Gy (range 5.99-8.29 Gy) and 2.31 Gy (range 0.88-7.08 Gy), respectively. A complete response (residual inactive scar tissue) was seen in four of the five focal tumours treated, with one tumour responding with a partial response (suspicious residual scar tissue). No acute or late side-effects occurred in patients treated with focal SRT. Only the patient treated with whole-eye SRT developed late effects of cataract and corneal ulceration. One patient suffered recurrence within the radiation field 5 months after focal SRT. Control of this recurrence was successful using chemotherapy and focal therapy. No eye has been enucleated. CONCLUSION Vision-sparing focal SRT for localised tumour masses in critical locations can control tumours with minimal side-effects and a minimal dose to the surrounding critical normal tissue.
Collapse
Affiliation(s)
- A Sahgal
- Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Millar BA, Moore S, Harrison BJ. Thyroid cancer management in North Trent. Case record review confirms the need for specialist care. Br J Surg 2002. [DOI: 10.1046/j.1365-2168.2000.01601-10.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
Background
The Calman–Hine Report mandates the need for specialist care of patients with cancer within the UK. The next round of accreditation will include an assessment of care available to patients with thyroid cancer. The Joint Thyroid Cancer Clinic in Sheffield allows secondary and tertiary referral to a multidisciplinary specialist team for the two million people of North Trent.
Methods
A retrospective case record review of the last 159 patients referred to the clinic by specialist and non-specialist surgeons was performed to assess surgical and pathological aspects of care, including preoperative, peroperative and postoperative management, as well as operative morbidity.
Results
A total of 37 surgeons at ten hospitals were involved in the initial management of 128 women and 31 men (mean age 53 (range 10–99) years) with thyroid cancer (111 differentiated, nine medullary, 16 anaplastic, 15 lymphoma, eight others), including 23 general surgeons (69 patients), ten ear, nose and throat surgeons (ten patients) and three specialist endocrine surgeons (66 patients). Non-specialist surgeons carried out 78 reoperative procedures. Histopathological review after referral by a specialist pathologist resulted in a change in diagnosis in 10 per cent of 125 patients (13 cases). Operation-specific surgical morbidity was recorded as follows:
Cancer Registry data indicated that a further 101 patients with thyroid cancer were never referred to the Joint Thyroid Cancer Clinic during the same period.
Conclusion
In North Trent, despite the presence of a longstanding and well established clinic, many patients with thyroid cancer do not receive specialist/multidisciplinary care. Patients are often treated by surgeons with little experience of thyroid cancer, and the rates of inaccurate pathological diagnosis and operative morbidity are unacceptably high in patients treated by non-specialist teams.
Collapse
Affiliation(s)
- B A Millar
- Weston Park Hospital and Department of Surgery, Northern General Hospital, Sheffield, UK
| | - S Moore
- Weston Park Hospital and Department of Surgery, Northern General Hospital, Sheffield, UK
| | - B J Harrison
- Weston Park Hospital and Department of Surgery, Northern General Hospital, Sheffield, UK
| |
Collapse
|